)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Connect Biopharma
Connect Biopharma (CNTB) investor relations material
Connect Biopharma Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary12 Aug, 2026
Executive summary
Advanced rademikibart, a next-generation antibody for asthma and COPD, with Phase 2 studies completed enrollment and topline data expected in September 2026.
Initiated a new Phase 2 IV study for rademikibart in August 2026 to bridge subcutaneous to IV administration for acute exacerbations.
Cash runway projected to last at least one year from August 2026.
Financial highlights
License and collaboration revenues were $2.8M for Q2 2026 and $2.9M for H1 2026, mainly from a regulatory milestone under the Simcere agreement.
Research and development expenses rose to $16.3M for Q2 2026 and $31.3M for H1 2026, driven by rademikibart clinical development.
General and administrative expenses decreased to $4.1M for Q2 2026 and $8.8M for H1 2026, reflecting lower professional fees.
Net loss was $17.3M for Q2 2026 and $36.7M for H1 2026, compared to $12.9M and $23.2M for the same periods in 2025.
Cash, cash equivalents, and short-term investments totaled $31.5M as of June 30, 2026.
Outlook and guidance
Management expects existing cash resources to fund operations for at least one year from August 2026.
Ongoing and future capital needs will be met through equity, debt, collaborations, or strategic transactions.
Topline data from key Phase 2 studies expected in September 2026, with plans to meet FDA for Phase 3 alignment.
Eligible for up to $99M in future milestone payments from Simcere collaboration.
Rademikibart IV bridging study objectives
Drivers of the 2026 R&D expense increase
Simcere partnership milestone payment potential
Rademikibart Phase 3 design and FDA alignment
Q2 2026 Simcere milestone and cost sharing
Seabreeze STAT IV study bridging strategy
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Connect Biopharma
- Rademikibart shows rapid, sustained efficacy and safety in asthma, COPD, and AD, with major market potential.CNTB
Corporate presentation - Rademikibart delivers rapid, durable airway improvements and is advancing toward pivotal SEABREEZE results.CNTBH.C. Wainwright 4th Annual BioConnect Investor Conference
- Rademikibart delivers rapid, sustained efficacy and safety in respiratory and dermatologic diseases.CNTBCorporate presentation
- Registering 6.13M shares for resale from a private placement; no proceeds to the company.CNTBRegistration filing
- Net loss rose to $19.4 million as R&D spending increased, with strong cash reserves and advancing trials.CNTBQ1 2026
- Strong clinical progress and extended cash runway position for key data readouts in 2026.CNTBQ4 2025
- IV rademikibart delivers rapid, sustained lung and skin efficacy with strong safety profile.CNTBStudy result
- Rapid-acting IL-4 antibody delivers durable efficacy in asthma/COPD, with key data and global milestones ahead.CNTBLeerink Global Healthcare Conference 2026
- Rademikibart targets acute asthma and COPD with rapid efficacy, aiming for major market impact.CNTBOppenheimer 36th Annual Healthcare Life Sciences Conference
Next Connect Biopharma earnings date
Q3 202613 Nov, 2026
Connect Biopharma
Next Connect Biopharma earnings date
Q3 202613 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage